Tags Archive Navigation
icon
-
Media ReleaseNovartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
-
Media ReleaseNovartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints
-
Media ReleaseNovartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease
-
Media ReleaseNovartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
-
Media ReleaseNovartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
-
Media ReleaseNovartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma
-
Media ReleaseNovartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
-
Media ReleaseNovartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer
-
StoryThe search for new options for patients with lung cancer
-
StoryThe future of chronic myeloid leukemia is evolving
-
StoryCan data from a heart disease trial lead to a potential cancer treatment?
-
StoryPartnering for improved cancer care around the globe
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- › Next page